Star Therapeutics has secured $200 million in private financing to advance its pipeline of therapies. The funding was co-led by OrbiMed and Janus Henderson Investors.
PRIVATEOct 23, 2026
Amount Raised
$200 Million
Round Type
Venture
South San FranciscoBiotechnology
Investors
New Leaf VenturesCormorant Asset ManagementCatalio Capital ManagementAgent CapitalJanus Henderson InvestorsOrbimed
Description
Star Therapeutics, a biotechnology company, has announced a $200 million private financing. This funding will help advance its pipeline aimed at developing life-changing therapies. The financing follows the acquisition of its subsidiary Vega Therapeutics. It was co-led by OrbiMed and Janus Henderson Investors, with participation from other investors.
Who to call at Star Therapeutics, and when
A new round usually means Star Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Star Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Star Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Star Therapeutics
Location
South San Francisco, California, United States
About
Star Therapeutics is a clinical stage biotechnology company discovering and developing best-in-class antibodies to create life-changing therapies for patients, initially addressing unmet needs in hematology and immunology. The company applies its expertise in antibody innovation to interrogate areas of biology that have been overlooked and have the potential for addressing multiple diseases with a single therapy. Our lead program, VGA039, has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with von Willebrand disease (VWD). As a subcutaneously self-administered antibody therapy with convenient dosing, VGA039 has the potential to significantly reduce the treatment burden for patients.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Star Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
South San FranciscoBiotechnology